Advertisement

Direct Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and Adults

Published:September 18, 2008DOI:https://doi.org/10.1053/j.gastro.2008.09.012

      Background & Aims

      Data regarding the health care costs of inflammatory bowel disease (IBD) in the United States are limited. The objectives of this study were to estimate the direct costs of Crohn's disease (CD) and ulcerative colitis (UC) in the United States, describe the distribution of costs among inpatient, outpatient, and pharmaceutical services, and identify sociodemographic factors influencing these costs.

      Methods

      We extracted medical and pharmacy claims from an administrative database containing insurance claims from 87 health plans in 33 states, occurring between 2003 and 2004. We identified cases of CD and UC using an administrative definition. For each case, we selected up to 3 non-IBD controls. Claims were classified as inpatient, outpatient, or pharmaceutical according to Current Procedural Terminology codes or National Drug Codes. Costs were based on the paid amount of each claim. IBD-attributable costs were estimated by subtracting costs for non-IBD patients from those for patients with IBD. Logistic regression was used to identify the sociodemographic factors affecting these costs.

      Results

      We identified 9056 patients with CD and 10,364 patients with UC. Mean annual costs for CD and UC were $8265 and $5066, respectively. For CD, 31% of costs were attributable to hospitalization, 33% to outpatient care, and 35% to pharmaceutical claims. The corresponding distribution for UC was 38%, 35%, and 27%, respectively. Costs were significantly higher for children younger than 20 years compared with adults, but this did not vary substantially by sex or region.

      Conclusions

      This study demonstrates a substantial economic burden of IBD and can be used to inform health policy.

      Abbreviations used in this paper:

      CI (confidence interval), OR (odds ratio)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Catlin A.
        • Cowan C.
        • Heffler S.
        • et al.
        National health spending in 2005: the slowdown continues.
        Health Aff (Millwood). 2007; 26: 142-153
        • Thorpe K.E.
        Factors accounting for the rise in health-care spending in the United States: the role of rising disease prevalence and treatment intensity.
        Public Health. 2006; 120: 1002-1007
        • Thorpe K.E.
        The rise in health care spending and what to do about it.
        Health Aff (Millwood). 2005; 24: 1436-1445
        • Thorpe K.E.
        • Florence C.S.
        • Howard D.H.
        • et al.
        The rising prevalence of treated disease: effects on private health insurance spending.
        Health Aff (Millwood). 2005; (W5-317-W5-25)
        • DeVol R.
        • Bedroussian A.
        • Charuworn A.
        An unhealthy America: the economic burden of chronic disease.
        Milken Institute, Santa Monica, CA2007
        • Longobardi T.
        • Jacobs P.
        • Bernstein C.N.
        Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey.
        Am J Gastroenterol. 2003; 98: 1064-1072
        • Cohen R.D.
        The quality of life in patients with Crohn's disease.
        Aliment Pharmacol Ther. 2002; 16: 1603-1609
        • McLeod R.S.
        • Churchill D.N.
        • Lock A.M.
        • et al.
        Quality of life of patients with ulcerative colitis preoperatively and postoperatively.
        Gastroenterology. 1991; 101: 1307-1313
        • Loftus Jr, E.V.
        Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences.
        Gastroenterology. 2004; 126: 1504-1517
        • Loftus Jr, E.V.
        The burden of inflammatory bowel disease in the United States: a moving target?.
        Clin Gastroenterol Hepatol. 2007; 5: 1383-1384
        • Kappelman M.D.
        • Rifas-Shiman S.L.
        • Kleinman K.
        • et al.
        The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States.
        Clin Gastroenterol Hepatol. 2007; 5: 1424-1429
        • Hay J.W.
        • Hay A.R.
        Inflammatory bowel disease: costs-of-illness.
        J Clin Gastroenterol. 1992; 14: 309-317
        • Feagan B.G.
        • Vreeland M.G.
        • Larson L.R.
        • et al.
        Annual cost of care for Crohn's disease: a payor perspective.
        Am J Gastroenterol. 2000; 95: 1955-1960
        • Lichtenstein G.R.
        • Yan S.
        • Bala M.
        • et al.
        Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease.
        Gastroenterology. 2005; 128: 862-869
        • Odes S.
        • Vardi H.
        • Friger M.
        • et al.
        Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation.
        Gastroenterology. 2006; 131: 719-728
        • Druss B.G.
        • Marcus S.C.
        • Olfson M.
        • et al.
        Comparing the national economic burden of five chronic conditions.
        Health Aff (Millwood). 2001; 20: 233-241
        • Stempel D.A.
        • Mauskopf J.
        • McLaughlin T.
        • et al.
        Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast.
        Respir Med. 2001; 95: 227-234
        • Bassi A.
        • Dodd S.
        • Williamson P.
        • et al.
        Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study.
        Gut. 2004; 53: 1471-1478
        • Hait E.
        • Bousvaros A.
        • Grand R.
        Pediatric inflammatory bowel disease: what children can teach adults.
        Inflamm Bowel Dis. 2005; 11: 519-527
        • Haller C.A.
        • Markowitz J.
        IBD in children: lessons for adults.
        Curr Gastroenterol Rep. 2007; 9: 528-532
        • Herrinton L.J.
        • Liu L.
        • Lafata J.E.
        • et al.
        Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings.
        Inflamm Bowel Dis. 2007; 13: 451-461
        • Bernstein C.N.
        • Blanchard J.F.
        • Rawsthorne P.
        • et al.
        Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study.
        Am J Epidemiol. 1999; 149: 916-924